Pediatric Radiation Therapy Registry

NCT07129317 | Recruiting DMC

• 2 other identifiers: J2563IRB00504065
• Study Type: observational
• Target: 5,000
• Locations: 1 country
• Sites: 2

Brief Summary

The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the long-term outcomes and toxicity of each patient. The registry will capture baseline clinical data, disease, toxicity, and quality of life outcomes. The goal is to include all pediatric patients undergoing proton therapy and photon therapy to enable future comparisons of treatment outcomes.

Conditions

Sarcoma; Pediatric Brain Tumors

Keywords

Pediatric; Brain tumor; Registry; Proton radiation; Radiation therapy; Photon radiation

Outcome Measures

Primary Outcomes (2)

• Overall Survival

  Measured from date of diagnosis until death, obtained from medical record notes

  Approximately 10 years

• Toxicity due to Radiation Therapy as assessed by number of patients with adverse events

  The number of patients that experience adverse events, obtained from medical record notes

  Approximately 10 years

Study Arms (3)

Pediatric brain tumors

Pediatric patients diagnosed with brain tumors requiring treatment with either proton or photon radiation therapy.

Pediatric sarcomas

Pediatric patients diagnosed with bone or soft tissue sarcomas requiring treatment with either proton or photon radiation therapy.

Non-brain-tumor and non-sarcoma

Eligibility Criteria

• Age: 0 Years - 26 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Pediatric brain tumor and bone and soft tissue sarcoma patients that are being treated with proton or photon radiation therapy.

You may qualify if:

• Treatment with either proton or photon radiation therapy.

You may not qualify if:

• Greater than 26 years old

Sponsors & Collaborators

• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: lead
• Clark Charitable Foundation Inc.: collaborator

Study Sites (2)

Sibley Memorial Hospital

Washington D.C., District of Columbia, 20016, United States

RECRUITING

Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States

RECRUITING

MeSH Terms

Conditions

Sarcoma; Brain Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Sahaja Acharya, MD

  SKCCC Johns Hopkins Medical Institution

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ethan Arnone, BS

CONTACT

2029192533; earnone3@jh.edu

Betsy Sawdy, MSN

CONTACT

2029192551; eburne10@jh.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2025
• First Posted: August 19, 2025
• Study Start: October 31, 2025
• Primary Completion (Estimated): September 1, 2035
• Study Completion (Estimated): September 1, 2040
• Last Updated: November 5, 2025

Record last verified: 2025-11

Locations

US (2)